The authors demonstrated that ADAM17 overexpression was associated with an advanced TNM stage and presence of lymph node metastasis, while there was no significant correlation between ADAM17 expression and tumour differentiation [71,72,80,81,82]. Here, ADAM17 is linked to metastatic malignant neoplasm in the lymph nodes.